{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000029","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.936682+00:00","generated_at":"2026-05-31T06:38:21.605537+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NovoCure CEO Asaf Danziger to retire Jan 1, 2025; CFO Ashley Cordova appointed CEO","bullets":["CEO Asaf Danziger, in role since 2002, retires Jan 1, 2025; will remain on board and advise until early 2026.","CFO Ashley Cordova named CEO effective Jan 1, 2025; she will stay as CFO until successor appointed.","COO Wilco Groenhuysen resigns effective Oct 1, 2024; Mukund Paravasthu promoted to COO.","Groenhuysen entered new employment agreement: base salary $615K/yr to Sept 2025 then $120K/yr to Apr 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000029","json":"https://secwatch.observer/filing/0001645113-24-000029.json","markdown":"https://secwatch.observer/filing/0001645113-24-000029.md","text":"https://secwatch.observer/filing/0001645113-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/nvcr-20240830.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:38:21.605537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b03bfc757","claim":"Ashley Cordova was appointed as Chief Executive Officer at NovoCure Ltd.","evidence_excerpt":"On September 3, 2024, the Company announced the appointment of Ashley Cordova, age 45, who is currently serving as the Company’s Chief Financial Officer, as the Chief Executive Officer of the Company and its respective direct and indirect subsidiaries and affiliates (together, the “Novocure Group”), effective January 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a6e3409779","claim":"Wilco Groenhuysen resigned as Senior Advisor at NovoCure Ltd.","evidence_excerpt":"On September 3, 2024, the Company also announced that Wilco Groenhuysen, the Company’s Chief Operating Officer, resigned effective October 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Advisor"}],"fact_type":"executive_change"},{"claim_id":"ba8ba5f9eb","claim":"Asaf Danziger resigned as Senior Advisor at NovoCure Ltd.","evidence_excerpt":"On September 3, 2024, Asaf Danziger, Chief Executive Officer of NovoCure Limited (the “Company”) resigned from that position effective January 1, 2025 and accepted a new role as Senior Advisor, effective January 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Advisor"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}